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Background: Th-2 cytokine milieu including interleukin 4 (IL-4) was detected in fibrotic lung diseases. Chronic
extrinsic allergic alveolitis (EAA) may be also accompanied by marked fibrogenesis. The aim of this study was to
determine if IL-4 and its receptor (IL-4R-alpha) play any role in the clinical presentation and pathogenesis of chronic
EAA.
Methods: Twenty patients originally investigated for interstitial lung disease and finally diagnosed affected with
chronic EAA and sarcoidosis were prospectively enrolled into the study. Concentrations of IL-4, IL-4R-aplha and total
protein were assessed in the bronchoalveolar lavage fluid (BALF) of all enrolled subjects as well as high resolution
computed tomography (HRCT) scores and pulmonary function tests.
Results: BALF IL-4R-alpha and total protein concentrations were significantly higher in chronic EAA patients (p <
0.05). Concentrations of BALF IL-4R-alpha were significantly higher in men than in women (p < 0.05) in EAA group.
Total protein BALF levels were significantly elevated in ex-smokers with EAA compared to nonsmokers (p < 0.05). A
positive correlation (p < 0.01) between IL-4R-alpha BALF concentrations and HRCT interstitial scores were observed
in chronic EAA group; the IL-4R-alpha/total protein ratio showed the same significant positive correlation. A
negative correlation between lung function results and IL-4R-alpha, and IL-4R-alpha/total protein as well, was also
found (p < 0.05).
Conclusions: We suggest a clinical relevance for the IL-4/IL-4R axis in the etiopathogenesis of chronic EAA.
IL-4R-alpha could serve as a potential biomarker of lung fibrogenesis.
Keywords: Chronic extrinsic allergic alveolitis, High resolution computed tomography score, Interleukin 4,
Interleukin 4 receptor, SarcoidosisBackground
Even though extrinsic allergic alveolitis (EAA) is among
the most frequently diagnosed interstitial lung diseases,
pathogenetic events leading to lung involvement need to
be elucidated. Originally, immune complex deposition
and related injuries were thought to play a major role in
EAA development [1]. Further studies showed the
potential of adoptive transfer of EAA by Th1 lympho-
cytes, and the influence of mainly Th1 cytokines and
chemokines on disease manifestation has been reported* Correspondence: martina.sterclova@ftn.cz
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reproduction in any medium, provided the or(namely: interferon gamma, and interferon gamma in-
duced protein 10) [2]. Later, Th2 cytokine milieu was
found to play a role in the etiopathogenesis of pulmon-
ary fibrosis in chronic EAA patients [3]. Interleukin-4
(IL-4) is a Th2 cytokine and has been found to take part
in the pathogenesis of fibrosis in the ‘bleomycin model,’
as well as in idiopathic pulmonary fibrosis (IPF) patients.
IL-4 is thought to be an important chemotactic factor
for fibroblasts and it can enhance both their prolifera-
tion and collagen production. Membrane bound and
soluble IL-4 receptors (IL-4R) have been described, espe-
cially IL-4R-alpha. The soluble form of IL-4R can have
both antagonist activity or can act as a carrier of IL-4
and its biological properties [4]. Furthermore, IL-4 wasal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Diagnostic criteria for chronic EAA used at
author’s institution













Histology pattern Granuloma, OP, DIP,
NSIP, UIP
BALF bronchoalveolar lavage fluid, DIP desquamative interstitial pneumonia,
DLco lung diffusing capacity for carbon monoxide, GGO ground glass opacities,
HRCT high resolution computed tomography, NSIP nonspecific interstitial
pneumonia, OP organising pneumonia, UIP usual interstitial pneumonia.
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tions [5]. Despite pulmonary fibrosis is the main histo-
pathological and radiological feature of chronic EAA,
the role of IL-4 and IL-4R in EAA pathogenesis has not
been studied yet.
The aim of this study was to determine if IL-4 and IL-
4R play any role in chronic EAA pathogenesis by: (i)
comparing bronchoalveolar lavage fluid (BALF) concen-
trations in chronic EAA and sarcoidosis patients (sarcoid-
osis being considered a typical Th1 mediated disease) and
(ii) looking for correlations among IL-4 and IL-4R BALF
concentrations and clinical parameters of patients with
chronic EAA (gender, smoking status, pulmonary function
tests, BALF differential cell counts, high resolution com-
puted tomography pattern of the disease).
Methods
Patients
Fourteen patients (7 men / 7 women, aged 59 ± 11
years, 7 non-smokers and 7 ex-smokers) originally in-
vestigated for interstitial lung disease and finally
diagnosed with chronic EAA were prospectively en-
rolled into the present study. A second control group was
formed by six patients diagnosed with sarcoidosis
according to the European Respiratory Society/American
Thoracic Society/ World Association of Sarcoidosis and
Other Granulomatous Disorders (ERS/ATS/WASOG)
criteria (4 men / 2 women, aged 46 ± 13 years, 2 non-
smokers, 3 ex-smokers, 1 current smoker, 4 patients sar-
coidosis stage 2, 2 patients stage 4) [6]. All participants
gave informed consent and the study was approved by
Ethics Committee of the ThomayerHospital and Insti-
tute of Clinical and Experimental Medicine, Prague,
Czech Republic. As part of the diagnostic work-up, all
patients provided a detailed medical history, underwent
blood tests including exclusion of laboratory signs of
autoimmune diseases, pulmonary function tests (spir-
ometry, lung diffusing capacity for carbon monoxide-
Dlco), bronchoscopy with bronchoalveolar lavage and
transbronchial biopsy, a high resolution computed tom-
ography of the chest (HRCT) and a surgical lung biopsy,
when diagnosis remained uncertain even after the above
mentioned diagnostic procedures (8 EAA patients, 4
sarcoidosis patients). Since there are no universally ac-
cepted diagnostic criteria for EAA, the criteria used in
this study are summarized in Table 1. Only patients with
probable/definite chronic EAA were included in the
study group.
Possible chronic EAA: negative history of exposure to
inhalation antigen+ BALF lymphocytosis+typical HRCT
pattern/histology pattern (see above in the Table).
Probable chronic EAA: positive history of exposure
to inhalation antigen+typical HRCT/histology pattern
(see above in the Table).Definite chronic EAA: positive history of exposure to
inhalation antigen+BALF lymhocytosis+typical HRCT/
histology pattern (see above in the Table).
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed during the
fiberoptic bronchoscopy under local anesthesia. The
bronchoscope was wedged into the segmental part of
the middle lobe. Five fractions of 50 ml of lukewarm
saline were instilled and after each instillation gently as-
pirated. Only samples with recovery > 50% were used
(mean recovery per one fraction 57 ± 20%). The re-
trieved fluid was mixed in a sterile container before div-
ision for further investigation. To assess the BAL fluid
(BALF) cell differential counts, 5 ml of BALF were
centrifuged and standard cytological sample was pre-
pared with Giemsa-Romanovski staining. Cells were
counted using a light microscope and a 125× objective;
cells in 100 fields were counted and percentages of al-
veolar macrophages, lymphocytes, neutrophils and eo-
sinophils were estimated.
Concentrations of IL-4R-alpha (CD-124) in the bron-
choalveolar lavage were determined using the ELISA
method (Uscn Life Science Inc, Houston, USA) according
to manufacturer’s instructions. A FlowCytomix human
Th1/Th2 11plex Ready-to-Use Kit (Bender MedSystems
Vienna, Austria) was used for quantitative detection of IL-
4 in the supernatants obtained from the BALF according
to the manufacturer’s instructions.
The concentration of total protein was measured spec-
trophotometrically using a bicinchoninic acid assay (BCA
kit; Pierce, Rockford, USA) following the manufacturer’s
Table 3 Results of pulmonary function tests, HRCT
alveolar and interstitial score of chronic EAA and
sarcoidosis patients
Chronic EAA Sarcoidosis p
FVC (% e.v.) 79,8 ± 17,8 86,2 ± 22,4 > 0,05
79 [55–121] 92,5 [42–101]
FEV1 (% e.v.) 84,0 ± 18,2 81,2 ± 19,9 > 0,05
81,5 [53–124] 87,5 [42–98]
Dlco (% e.v.) 47,9 ± 19,7 62,8 ± 17,5 < 0,05
42 [30–91] 55 [46–98]
HRCTa 1,7 ± 1,0 2 ± 1,6 > 0,05
1,5 [0–3] 2 [0–4]
HRCTi 1,9 ± 1,0 1,5 ± 1,3 > 0,05
2 [1-4] 1 [0–3]
Dlco lung diffusing capacity for carbon monoxide, e.v. expected value, FEV1
forced expired volume in 1 second, FVC forced vital capacity, HRCTa high
resolution computed tomography alveolar score, HRCTi high resolution
computed tomography interstitial score. Values are presented as mean ± SD/
median [min-max value].
Table 4 BALF cell counts, total protein concentrations, IL-
4 and IL-4Ralpha concentrations in chronic EAA and
sarcoidosis patients
Chronic EAA Sarcoidosis p
Alveolar macrophages (%) 65,1 ± 24,8 81,0 ± 9,9 > 0,05
72,5 [12–94] 80,5 [72–91]
Polymorphonuclear
cells (%)
6,4 ± 6,6 4,5 ± 5,1 > 0,05
5 [1-28] 2,5 [1-12]
Lymphocytes (%) 19,5 ± 21,9 15,8 ± 8,4 > 0,05
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BALF dilutions, the IL-4/total protein and IL-4R/total
protein ratios were used to validate correlations among
clinical parameters and interleukin’s BALF concentrations.
Pulmonary function tests
Forced vital capacity (FVC) and forced expiratory vol-
ume in one second (FEV1) were obtained during initial
investigations and at the one year follow up using a
ZAN 100 Flowhandy II (Inspire, Oberthulba, Germany).
ERS/ATS performance criteria were used for the test
[7]. The predicted spirometry values complied with
those of the European Coal and Steel Community [8].
Diffusing capacity for CO (Dlco) was obtained using a
ZAN 300 CO-diffusion (Inspire, Oberthulba, Germany)
on the same day as spirometry was performed. The Dlco
was measured using the single-breath method. Values
were expressed as a percentage of the predicted value.
High resolution computed tomography
All enrolled subjects underwent a HRCT of the chest dur-
ing the initial investigation. HRCT scans were performed
using a LightSpeed VCT XT scanner. HRCT alveolar and
interstitial scores were assessed by a pulmonologist expe-
rienced in radiology and carried out according to Gay SE
et al. (Table 2) [9].
Statistical methods
Results are expressed as the mean ± standard deviation
(SD)/ median [min-max value]. Differences between two
variables were assessed using the Mann–Whitney U test.
The Spearman’s correlation was used to analyze correla-
tions among variables. For all statistical methods, p <
0.05 was regarded as significant.
Results
Results of pulmonary function tests and HRCT alveolar
and interstitial scores in both groups (chronic EAA vs.
sarcoidosis) are presented in Table 3.Table 2 HRCT scoring system according to Gay SE et al.*
Score Alveolar Interstitial
0 No alveolar disease No interstitial disease
1 GGO < 5% Septal thickening, no honeycombing
2 GGO < 25% HC/ septal thickening < 25%
3 GGO 25-49% HC/septal thickening 25-49%
4 GGO 50-75% HC/septal thickening 50-75%
5 GGO > 75% HC/septal thickening > 75%
Scored fields = peak of aortic arch, tracheal bifurcation, most prominent
convexity of the right ventricle, and peak of the right cupola of diaphragm.
Mean interstitial and alveolar scores were counted.
GGO ground glass opacity, HC honeycombing.
*[9].BALF differential cell counts, total protein concentra-
tions, IL-4 and IL-4R-alpha concentrations are summa-
rized in Table 4. Correlations among BALF total protein,
IL-4 and IL-4R-alpha concentrations and clinical pa-
rameters (gender, smoking status, pulmonary function
tests, HRCT, BALF differential cell counts) are summa-
rized below.
Concentrations of BALF IL-4R-alpha were significantly
higher in men diagnosed as EAA than in women (p <8 [2–74] 15,5 [8/24]
Eosinophils (%) 7,3 ± 8,1 1,3 ± 1,1 > 0,05
6,5 [0–25] 0,5 [0–4]
IL-4 (pg/ml) 34,9 ± 31,0 25,5 ± 18,0 > 0,05
29,2 [0–96,4] 25,8 [0–50,5]










IL-4 interleukin 4, IL-4Ralpha alpha subunit of interleukin 4 receptor.
Values are presented as mean ± SD/ median [min-max value].
Figure 1 Positive correlation between HRCT interstitial score
and IL4R BALF concentrations in chronic EAA patients. BALF,
bronchoalveolar lavage fluid; EAA, extrinsic allergic alveolitis; HRCT,
high resolution computed tomography; IL-4R, interleukin 4
receptor (pg/ml).
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elevated in ex-smokers with EAA compared to non-
smokers (p < 0.05). Positive correlation (p < 0.01) be-
tween IL-4R-alpha BALF concentrations and HRCT
interstitial scores was observed in the chronic EAA
group (R=0,74). The IL-4R-alpha/total protein ratio also
showed the same significant positive correlation (R=0,71)
[Figures 1 and 2]. Negative correlations among FVC/IL-4
Ralpha(R= −0,73), IL-4 Ralpha/total protein (R=−0,66),
FEV1/IL-4 R alpha (R= −0,70) , IL-4 R alpha/ total protein
(R= −0,63), Dlco (IL-4 R alpha :R=−0,67, IL-4R alpha/total
protein: R= −0,57) and IL-4R-alpha as well as IL-4R-alpha/
total protein were found (p < 0.05) [Figures 3 and 4]. No
further significant correlations were observed in the
chronic EAA group.
As to sarcoidosis patients, correlations were not
assessed because of the small number of enrolled patients.
Discussion
The present study was aimed to determine whether Th2
cytokine IL-4 and its soluble receptor IL-4R-alpha take
part in the fibrogenic process seen in chronic EAA,
which is thought to exhibit a Th2 cytokine milieu. Data
obtained from chronic EAA patients were compared to
sarcoidosis patients. Sarcoidosis is considered to be aFigure 2 Positive correlation between HRCT interstitial score and IL-4
bronchoalveolar lavage fluid; EAA, extrinsic allergic alveolitis; HRCT, high restypical Th1 disease, moreover studies of IL-4R gene
polymorphisms have showed no association with sar-
coidosis, and no differences were found in IL-4 BALF
concentrations from sarcoidosis patients compared to
healthy controls [10,11].
In this study the patients groups differed in age, and
this is not surprising as the usual age of sarcoidosis
manifestation is < 40 years. None of chronic EAA pa-
tients were considered professional EAA, and it could be
related to lower age [12].
Initially, BALF concentrations of IL-4 and IL-4R-alpha
were compared in chronic EAA and sarcoidosis patients.
Even though the difference was not statistically signifi-
cant, higher IL-4 concentrations were observed in EAA
group. Previous studies have documented the role of IL-
4 as well as interferon gamma in the pathogenesis of
EAA, both cytokines being produced by non-immune
cells [13]. The effect of IL-4 on fibrosis development in
EAA patients varies form study to study. Some authors
even documented a remarkable improvement in murine
EAA after IL-4 administration, while others did not find
such effect for this cytokine [14,15]. Even though IL-4
augments the effects of fibroblasts in in vitro studies,
its contribution to fibro-proliferation in EAA patients
has not been studied. Nevertheless studies performed in
IPF patients have shown a clear role for IL-4 in
fibrogenesis; distinct polymorphisms of the gene for IL-
4 have been associated with more severe radiological
involvement [16,17]. Because skewing of the immune
response from Th1 in the reversible stages of the dis-
ease to Th2 in the later fibrotic stages has been ob-
served, we might think that the role of IL-4/IL-4R
could fluctuate according to the manifestation of the
disease. Chronic EAA may share radiologic as well as
histological features of usual interstitial pneumonia and
perhaps IL-4 can play a similar role in IPF and chronic
EAA. According to the studies by Pechkovsky et al., IL-
4 is able to induce further expression of IL-4R, which
together with the above mentioned findings may sug-
gest a link to higher concentrations of IL-4, resulting in
higher concentrations of IL-4R-alpha and more pro-
nounced fibro-proliferation [18].R/total protein in BALF of chronic EAA patients. BALF,
olution computed tomography; IL-4R, interleukin 4 receptor (pg/ml).
Figure 3 Negative correlations among IL-4R concentrations in BALF and FVC, FEV1 and DLco in chronic EAA patients. BALF,
bronchoalveolar lavage fluid; DLco, lung diffusing capacity for carbon monoxide, EAA, extrinsic allergic alveolitis; e.v., expected values; FEV1, forced
expired volume in 1 second; FVC, forced vital capacity; HRCT, high resolution computed tomography; IL-4R, interleukin 4 receptor (pg/ml). FVC,
FEV1, DLco expressed in % of expected value.
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higher BALF total protein concentrations and IL-4R-alpha
(p < 0.05) were accompanied by non-significantly higher
HRCT interstitial scores in chronic EAA patients. We can
speculate that BALF soluble IL-4R-alpha concentrations
perhaps could be an even more sensitive marker of fibro-
sis than the more commonly mentioned HRCT [19,20].
The second aim of this study was to determine if an
association between IL-4/IL-4R-alpha and EAA etiopa-
thogenesis could be supported by a correlation between
BALF concentrations and the clinical presentation of the
disease (i.e., BALF differential cell count, pulmonary
function tests and HRCT scores). Because there were
only six patients in the sarcoidosis group, correlations
were not performed for this group. A positive correl-
ation between HRCT interstitial scores and IL-4R-alpha
BALF concentrations was observed, as well as a negative
correlation relative to FVC, FEV1,Dlco and IL-4R-alpha
BALF concentrations. The relevance of this finding was
supported by the same results of IL-4R-alpha adjusted
for BALF total protein concentrations. These observa-
tions might suggest that IL-4R-alpha acts like a carrier
of biological functions of IL-4 in chronic EAA with
HRCT signs of fibrotic lung impairment.Figure 4 Negative correlations among IL-4/total protein in BALF and
lavage fluid; DLco lung diffusing capacity for carbon monoxide; EAA, extrins
in 1 second; FVC, forced vital capacity; HRCT, high resolution computed tom
expressed in % of expected value.BALF total protein concentration in EAA patients with
a history of smoking was significantly higher than in
non-smoking patients. This findings agree with the re-
sults of Sato et al., even though their study measured al-
bumin concentrations [21]. Others have found lower
concentrations of proteins and mRNAs in smoking sub-
jects [22,23]. This discrepancy may be due to the fact
that, while acute exposure to cigarette smoke reduces
blood-airway permeability, chronic exposure to smoke
may disrupt the endothelial barrier integrity and thus in-
fluence endothelial permeability [24,25]. Thus a history
of smoking could be an important factor influencing
concentrations of various proteins in BALF.
It can be objected that smoking (or exposure to nico-
tine) was thought to be a protective factor for granu-
lomatous involvement in EAA patients [26]. However,
Furuiye et al. showed that long term smoking may lead
to more pronounced fibrogenesis even in EAA subjects,
probably because cigarette smoke is composed by many
substances, some of which could possibly have pro-
fibrotic effects. It also should be kept in mind that smok-
ing is a risk factor for other interstitial lung diseases
including IPF and rheumatoid arthritis associated inter-
stitial lung disease [27].FVC, FEV1 and DLco in chronic EAA patients. BALF, bronchoalveolar
ic allergic alveolitis; e.v., expected values; FEV1, forced expired volume
ography; IL-4R, interleukin 4 receptor (pg/ml). FVC, FEV1, DLco
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were found to be higher in men with EAA than in
women. There is no consistent information concerning
gender effect on EAA manifestation, perhaps because
most studies found in literature concern special types of
EAA (farmer’s lung, pigeon breeder’s lung, etc.). On the
other hand, interstitial lung diseases, like IPF, dominate
in the male population. Of course, smoking status has to
be considered, and smoking is still more common in
men than in women in most countries including the
Czech Republic. However, the effect of gender on immune
reactions has been reported by many authors. Pinzan et al.
observed different immunological reactions in men and
women infected by Paracoccidioidesbrasiliensis infection
[28]. According to results of this study, men who were
more often infected presented with a dominant Th2
immune response, while women exhibited a Th1 im-
mune response. Different immune responses are usually
explained by the influence of estrogen or testosterone
on different T cell populations, resulting in different
cytokine milieu [29,30]. Murine studies have shown that
not only gender of infected mice, but also IL-4 alpha
status can influence outcomes of some infectious dis-
eases [31]. As mentioned above, higher BALF concen-
trations were associated with more severe radiological
and pulmonary function test deterioration. It is possible
that differences in IL-4R-alpha expression between
males and females are part of different manifestations of
the condition and perhaps outcomes of some interstitial
lung diseases.
In our opinion the present study has several limita-
tions. First of all, the number of enrolled patients was
small, however the study was performed prospectively
and consecutive patients suspected of interstitial lung
disease were enrolled, among which we finally chose
those with a definite diagnosis of chronic EAA or sar-
coidosis. We assessed the concentrations of IL-4R-alpha,
which is not only part of IL-4R, but also of the IL-13 re-
ceptor. Nevertheless, the soluble form of IL-13R was
formed by IL-13R-alpha-2 and IL-4R-alpha may be part
of a membrane bound IL-13R.
Conclusions
BALF IL-4R-alpha concentrations were significantly
higher in chronic EAA than in sarcoidosis patients. Fur-
thermore, their BALF IL-4R-alpha concentrations corre-
lated with the extent of fibrotic changes assessed using
HRCT and with pulmonary function tests impairment,
suggesting a relevance to the pathogenesis of chronic
EAA. The use of IL-4RA as a potential fibrogenic
marker in chronic EAA patients should be further
assessed. Its elevated concentrations found in BALF
obtained at the time of diagnosis could select patients
with more fibrotic potential. Such a finding can be usefulin treatment decision and in selected cases could lead to
earlier discussion about possible need for lung trans-
plantation. Higher total protein BALF concentrations in
ex-smokers may suggest higher endothelial cell perme-
ability, which may affect concentrations of other proteins
in BALF as well. BALF concentrations of IL-4R-alpha
were significantly higher in males with chronic EAA.
The gender effect on chronic EAA manifestation needs
further study.
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